azathioprine has been researched along with Bulbar Palsy in 2 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Polymyositis is an inflammatory myopathy which, like SCD, may present with myalgia but is usually associated with proximal muscle weakness." | 1.42 | Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease. ( Bali, S; D'Cruz, D; Inusa, BP; Lazaro, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bali, S | 1 |
| D'Cruz, D | 1 |
| Lazaro, M | 1 |
| Inusa, BP | 1 |
| Ong, SG | 1 |
| Ding, HJ | 1 |
2 other studies available for azathioprine and Bulbar Palsy
| Article | Year |
|---|---|
Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease.
Topics: Adolescent; Adrenal Cortex Hormones; Anemia, Sickle Cell; Anti-Inflammatory Agents; Autoimmunity; Az | 2015 |
Patient with statin-associated immune-mediated necrotizing myopathy presenting with subcutaneous edema, persistent bulbar weakness and absent anti-HMGCR.
Topics: Aged; Autoantibodies; Azathioprine; Biopsy; Bulbar Palsy, Progressive; Edema; Glucocorticoids; Human | 2017 |